demonstrated statistically significant

Related by string. * demon strated . demonstrating . Demonstrating : XIENCE V demonstrated . demonstrating knives mops . demonstrated clinically meaningful / Statistically . STATISTICALLY : statistically significant improvement . statistically significant differences . statistically significant correlation / signifi cant . sig nificant : statistically significant reduction . Significant Items * *

Related by context. All words. (Click for frequent words.) 68 demonstrated clinically meaningful 67 achieved statistical significance 66 secondary endpoints 65 primary efficacy endpoint 65 Secondary endpoints included 64 secondary endpoint 64 primary endpoint 64 primary endpoints 63 statistically significant improvement 63 Secondary endpoints include 62 desvenlafaxine succinate 61 secondary efficacy endpoints 61 placebo 61 mg BID 61 placebo p 61 mg QD 60 Secondary endpoints 60 lopinavir r 60 Montgomery Asberg Depression 60 #mg/day [001] 59 plus methotrexate 59 mcg QD 59 placebo p = 59 #mg BID [003] 59 Negative Syndrome 59 tapentadol ER 58 p = #.# [004] 58 8mg/kg 58 evaluable 58 pharmacokinetics PK 58 MADRS 58 GERD symptom 58 p = #.# [002] 58 tiotropium 58 statistically significant 58 4mg/kg 58 #mg BID [001] 58 achieved ACR# 58 primary efficacy endpoints 57 #μg [002] 57 oral rivaroxaban 57 HDRS 57 Rating Scale MADRS 57 pharmacokinetic PK 57 Scale PANSS 57 lumbar spine BMD 57 pharmacodynamic 57 CIMZIA TM 57 clinically meaningful 57 #.#/#.# mmHg [001] 57 plus prednisone 57 ACTEMRA TM 57 oxycodone CR 57 glycosylated hemoglobin levels 57 YMRS 57 PANSS 57 mg TID 57 mg dose 57 administered subcutaneously 57 ADAS Cog 57 tumor progression TTP 57 CIMZIA TM certolizumab pegol 57 discontinuations due 56 ADCS CGIC 56 abdominal pain abdominal discomfort 56 placebo controlled 56 plus MTX 56 P = .# 56 progression TTP 56 ADAS cog 56 Pharmacokinetic 56 tolerability 56 TLUS 56 statistically significant p 56 Pain Intensity 56 tolvaptan 56 fosbretabulin 56 ascending doses 56 retinal thickness 56 Secondary efficacy endpoints 56 #mg/day [002] 56 MADRS score 56 bosentan 56 Pegasys ® 56 headache nasopharyngitis 56 median PFS 56 avosentan 56 neurologic progression 56 blood Phe 56 evaluable patients 56 fasting plasma glucose FPG 56 statistically significant reduction 56 Montgomery Åsberg Depression 56 UPDRS 56 timepoint 56 FOLFOX4 56 REYATAZ r 56 Free Survival PFS 56 pharmacodynamic PD 55 prospectively defined 55 Psoriasis Area 55 #mg QD [001] 55 tolterodine ER 55 virologic response 55 adalimumab 55 CNS LS 55 dapagliflozin plus 55 mcg BID 55 lumbar spine bone 55 ATACAND 55 Pharmacokinetics PK 55 tipranavir r 55 PANSS scores 55 Alzheimer Disease Assessment 55 symptom severity 55 ALVESCO 55 mg kg dose 55 LPV r 55 teriflunomide 55 demonstrated antitumor activity 55 ACR# [002] 55 eszopiclone 55 LEXIVA r 55 ULORIC 55 pharmacokinetic profiles 55 colesevelam HCl 55 lispro 55 prespecified 55 Crohn Disease Activity 55 secondary efficacy endpoint 55 trough FEV1 55 peginterferon alfa 2b 55 spontaneous bowel movements 55 ACTEMRA 55 IFN α 55 MoxDuo TM IR 55 efficacy endpoints 55 KRN# 55 rosuvastatin #mg 55 zonisamide SR 55 patients evaluable 55 clinically meaningful improvements 55 morphometric vertebral fractures 55 NPH insulin 55 5-FU/LV 55 3mg/kg 55 viral kinetics 55 FOLFIRI 55 nasal symptom 55 mg/m2 dose 54 octreotide LAR 54 dose dependently 54 insulin detemir 54 solifenacin 54 VELCADE melphalan 54 free survival PFS 54 rotigotine 54 novel histone deacetylase 54 ADCS ADL 54 chlorambucil 54 p = 54 APTIVUS r 54 Monotherapy 54 certolizumab 54 #mg/m# [002] 54 Aptivus ® 54 Efficacy 54 liver histology 54 weekly subcutaneous injections 54 WOMAC pain 54 randomized 54 alfa 2a 54 IPSS 54 statistically significant p = 54 IR prednisone 54 mg qd 54 guanfacine extended release 54 plus dexamethasone 54 mcg kg 54 PASI scores 54 analgesic efficacy 54 Cmax 54 lopinavir r arm 54 NLX P# 54 Primary endpoints 54 treatment emergent adverse 54 melphalan prednisone 54 CorVue ™ 54 icatibant 54 TAXUS ATLAS 54 ascending dose 54 EURIDIS 54 RG# [001] 54 Unified Parkinson Disease 54 Flu Cy 54 clodronate 54 mg ustekinumab 54 serum urate 54 active comparator 54 PANSS total 54 safinamide 54 mucosal healing 54 blood Phe levels 54 plus COPEGUS 54 Lupuzor ™ 54 methotrexate MTX 54 CANCIDAS 54 Initiated Phase 54 carboplatin paclitaxel 54 FOLFOX 54 pramipexole 54 tirofiban 54 log# 54 mitoxantrone plus 54 Tolerability 54 RoACTEMRA 53 HAQ DI 53 HAMD 53 randomized #:#:# 53 lipid parameters 53 prospective randomized controlled 53 ritonavir boosted 53 galiximab 53 receiving golimumab 53 SSRI citalopram 53 abacavir lamivudine 53 Brief Psychiatric 53 #mg QD [002] 53 achieve statistical significance 53 SCH # 53 LEVADEX 53 decitabine 53 SPIRIT FIRST 53 PEG IFN 53 certolizumab pegol 53 FEV1 53 randomized double 53 saline placebo 53 statistically significant differences 53 timepoints 53 etanercept 53 evaluating tivozanib 53 Randomized Evaluation 53 multicenter randomized controlled 53 composite endpoint 53 diabetic neuropathic pain 53 ACE inhibitor ramipril 53 pharmacodynamics PD 53 Score IPSS 53 somatostatin analog 53 insulin glargine 53 estramustine 53 inflammatory lesions 53 #ug [001] 53 comparator arm 53 primary hypercholesterolemia 53 plasma leptin 53 Phase 2a 53 #mg/kg [002] 53 tolerability profile 53 WOMAC 53 fasting plasma glucose 53 catheter occlusion 53 TRANSFORMS 53 Median PFS 53 low dose cytarabine 53 lanthanum carbonate 53 urinary N telopeptide 53 SBM frequency 53 randomized placebo controlled 53 docetaxel chemotherapy 53 adjunctive placebo 53 ADHD RS 53 International Prostate Symptom 53 subcutaneously administered 53 TO AVOID PREGNANCY WHILE 53 Capesaris 53 Scale EDSS 53 n = 53 dyskinesia PD LID 53 pegylated interferon alfa 2b 53 Parkinson disease levodopa induced 53 linaclotide treated 53 AUA Symptom Score 53 salmeterol fluticasone 53 pharmacokinetics 53 dose cohorts 53 SVR# 53 CIMZIA R 53 mg/# mg [001] 53 XIENCE V demonstrated 53 Phase 2a clinical 53 pharmacokinetic 53 Dual Opioid 53 multicentre randomized 53 HBeAg negative patients 52 intravascular hemolysis 52 doxorubicin cyclophosphamide 52 -#.# log# copies mL 52 μg dose 52 plus ribavirin 52 candesartan cilexetil 52 elagolix 52 ibandronate 52 leuprorelin 52 Traficet EN 52 oral prodrug 52 azacitidine 52 ACR# response 52 unfractionated heparin UFH 52 ribavirin RBV 52 paliperidone ER 52 multicenter randomized double 52 inhaled iloprost 52 oral antidiabetic medication 52 alanine aminotransferase ALT 52 unresectable HCC 52 BRIM2 52 aripiprazole 52 ACR# ACR# 52 pyridostigmine 52 ug dose 52 Newly Diagnosed Multiple Myeloma 52 alteplase 52 reach statistical significance 52 Controlled Trial 52 Q2W 52 AGILECT ® 52 plus gemcitabine 52 AEGR 52 AVOREN 52 Randomized Phase 52 Visual Analog Scale 52 REYATAZ r arm 52 virologic 52 Global Impression 52 peginterferon alfa 2a 52 Pegasys plus Copegus 52 MEND CABG 52 undetectable HBV DNA 52 Phase #b/#a trial 52 Xanafide 52 FOLPI 52 alpha 2a 52 PEGPH# 52 Scale cognitive subscale 52 QD dosing 52 irbesartan 52 LEXIVA 52 phonophobia 52 mg doses 52 mcg dose 52 atazanavir ritonavir 52 CI -#.# 52 timolol 52 nausea photophobia 52 dose dexamethasone 52 HIV RNA 52 TNSS 52 imatinib therapy 52 sweat chloride 52 PEGylated anti 52 Severity Index PASI 52 dose cytarabine 52 Linagliptin 52 valsartan 52 TMC# C# 52 Phase Ib clinical 52 HAM D# 52 pharmacokinetic profile 52 Phase 1b 52 Pegylated Liposomal Doxorubicin 52 docetaxel 52 FOLFIRI alone 52 XIENCE V PROMUS Stent 52 5 Fluorouracil 52 Demonstrates Significant 52 insulin degludec 52 mg kg 52 antiviral efficacy 52 oral diclofenac 52 Randomized Double Blind Placebo 52 serum cortisol 52 incidence ≥ 52 #mg/m# [001] 52 viral kinetic 52 Pred Forte 52 annualized relapse 52 incontinence episodes 52 RLAI 52 lacosamide 52 adefovir 52 tolterodine 52 fluticasone salmeterol 52 CORD II 52 IRLS 52 statistically significant superiority 52 ALT normalization 52 oral olanzapine 52 placebo controlled Phase 52 fluticasone furoate 52 F FDG PET 52 LANTUS R 52 monotherapy 52 BARACLUDE ® 52 serum triglycerides 52 FEMALES SHOULD BE ADVISED 52 Phase 2b study 52 pregabalin 52 events AEs 52 LVEF 52 insulin lispro 52 multicenter randomized placebo controlled 52 Median progression 52 Tiotropium 52 glycosylated hemoglobin HbA1c 52 mg kg BID 52 μg kg 52 ropivacaine 52 INCB# [001] 52 sitagliptin 51 CLARITY study 51 baminercept 51 double blind placebo 51 MAP# 51 RE LY ® 51 Azixa 51 randomized #:# 51 sUA 51 pharmacokinetic parameters 51 peg IFN 51 pharmacokinetic PK study 51 dosing cohorts 51 IFN alfa 51 disease progression TTP 51 double blinded randomized 51 corticosteroid dose 51 Tarceva TM 51 log# IU mL 51 Index CDAI 51 methotrexate monotherapy 51 exploratory endpoints 51 Oral Fingolimod 51 placebo controlled clinical 51 plasma HCV RNA 51 serum phosphorus 51 rapid virologic response 51 REMINYL ® 51 #mg dose [003] 51 APPRAISE 51 QTc 51 budesonide formoterol 51 Phase IIIb 51 HbA1c levels 51 lopinavir ritonavir 51 administered orally 51 posttreatment 51 HGS ETR2 51 Study Evaluating 51 interferon alfa 51 clinically meaningful improvement 51 mcg Albuferon 51 Neuropsychiatric Inventory NPI 51 double blinded placebo 51 Protelos 51 glycoprotein IIb IIIa inhibitor 51 biphasic insulin aspart 51 Mean Symptom Complex 51 GAMMAGARD 51 QTcF 51 Phase IIa clinical 51 multicenter prospective 51 pyrimidine nucleoside analog 51 antiviral activity 51 log# copies mL 51 liposomal formulation 51 relapsing multiple sclerosis 51 symptomatic VTE 51 metabolic parameters 51 budesonide pMDI 51 bolus injection 51 bronchodilation 51 plasma uric acid 51 sumatriptan naproxen sodium 51 Bosutinib 51 leukemia AML 51 mg administered orally 51 divalproex sodium 51 Fibromyalgia Impact Questionnaire 51 rimonabant #mg 51 prednisone prednisolone plus 51 q#h 51 Taxotere ® 51 NIS LL 51 Omacetaxine mepesuccinate 51 hyperphenylalaninemia HPA due 51 R# #mg BID 51 oral ibandronate 51 KRAS mutant tumors 51 GSK# [001] 51 multicenter placebo controlled 51 subcutaneous injections 51 PEG Intron 51 intermittent dosing 51 placebo controlled randomized 51 ataluren 51 venlafaxine XR 51 PD LID 51 methacholine challenge 51 serum IGF 51 splenectomized 51 Phase 1a clinical 51 Ostarine 51 vidofludimus 51 #mg dose [001] 51 sunitinib 51 FOLFOX6 chemotherapy regimen 51 prespecified secondary 51 pegylated liposomal doxorubicin 51 Pivotal Phase III 51 ciclesonide 51 Thrombolysis 51 citalopram 51 Primary Endpoint 51 Engerix B 51 ancrod 51 subanalysis 51 QTc intervals 51 IBDQ 51 ABC/3TC 51 CCyR 51 Randomized Double Blind 51 UPDRS motor 51 tolerability profiles 51 HCV RESPOND 2 51 plasma folate 51 Acute Ischemic Stroke 51 doxorubicin docetaxel 51 dexamethasone 51 trials RCTs 51 oral levofloxacin 51 STX# 51 HCV RNA 51 dexamethasone Decadron 51 sirolimus eluting stent 51 CombAT 51 octreotide 51 dacarbazine 51 glimepiride 51 LT NS# 51 dosage regimens 51 Androxal TM 51 single ascending dose 51 Phase 2b clinical 51 efficacy endpoint 51 milatuzumab 51 -#.# mg dL [002] 51 prospective multicenter randomized 51 cytogenetic response 51 infarct size 51 plasma cortisol 51 endoscopic remission 51 PREZISTA r 51 Events MACE 51 gout flares 51 5 HT2A 51 #:# randomization 51 PreCISe 51 PSADT 51 Epoetin Alfa 51 moderate renal impairment 51 Peg IFN 51 selective modulator 51 antidepressant efficacy 51 FOLFOX6 51 clinically relevant 51 subcutaneous SC 51 Pharmacokinetic PK 51 dose regimens 51 HBeAg positive patients 50 MoxDuo IR 50 trospium 50 relapsed MM 50 Trial Evaluating 50 fructosamine 50 nadolol 50 aspartate aminotransferase 50 metformin monotherapy 50 hip BMD 50 evaluating REVLIMID 50 Decitabine 50 mg simvastatin 50 bortezomib 50 lymphopenia 50 mITT population 50 activated partial thromboplastin 50 canakinumab 50 multiple ascending dose 50 fosamprenavir 50 pharmacodynamics 50 VaD 50 Antiviral Activity 50 pharmacokinetic PK profile 50 achieved CCyR 50 pravastatin 50 coadministration 50 -#.# mg dL [001] 50 Relapsing Multiple Sclerosis 50 attain statistical significance 50 HOMA IR 50 Amrubicin 50 pharmacodynamic parameters 50 Double Blind Randomized 50 Phase 1b clinical 50 multicenter Phase 50 BPH symptom 50 Gabapentin GR 50 Intravitreal 50 custirsen 50 Phase IIb clinical 50 Doxil ® 50 quetiapine XR 50 viral load 50 cisplatin vinorelbine 50 AUC0 50 #mg ritonavir 50 Demonstrated Significant 50 Apoptone 50 dimebon 50 Randomized Phase II 50 interferon gamma 1b 50 #mg BID [002] 50 tenofovir emtricitabine 50 GHRH 50 placebo fluoxetine 50 Tasimelteon 50 non inferiority 50 nicardipine 50 IIIa inhibitor 50 MERIT ES 50 mcg linaclotide 50 randomized multicenter 50 apolipoprotein B 50 FOSRENOL ® 50 selective androgen receptor modulator 50 tapentadol IR 50 visilizumab 50 mg RDEA# 50 erlotinib Tarceva ® 50 standard chemotherapy regimen 50 recurrent glioblastoma multiforme 50 Placebo Controlled 50 placebo PBO 50 Demonstrate Significant 50 plus prednisone prednisolone 50 PANSS Positive 50 albiglutide 50 mirtazapine 50 ceftazidime 50 6R BH4 50 VcMP 50 Phase 2b Clinical Trial 50 CK # plasma 50 Phase IIa 50 BoNTA 50 celgosivir 50 plasma concentrations 50 BARACLUDE r 50 Denufosol 50 Major Adverse Cardiac 50 daunorubicin 50 mitoxantrone 50 dose dose escalation 50 tasimelteon 50 ALGRX 50 multicenter randomized 50 Interferon beta 1a 50 EQ 5D 50 multicenter Phase III 50 Imprime PGG 50 NEVO ™ 50 CD4 + cell 50 Initiate Phase 50 interferon alfa 2b 50 Score DAS 50 neurocognitive function 50 prospective multicenter 50 Inventory BPI 50 zolmitriptan 50 blind randomized 50 infliximab monotherapy 50 Peginterferon 50 treatment naive genotype 50 sorafenib Nexavar 50 relapsed myeloma 50 TMC# r 50 rHuPH# 50 Multiple Ascending Dose 50 subscales 50 pharmacokinetic studies 50 dehydroepiandrosterone sulfate 50 glatiramer acetate 50 fasting insulin 50 Laquinimod 50 WOMAC TM 50 gemcitabine carboplatin 50 OXi# 50 QoL 50 atheroma volume 50 gastrointestinal motility 50 edoxaban 50 cisplatin gemcitabine 50 GI motility 50 mGluR5 negative 50 torsemide ER 50 PREZISTA ritonavir 50 TEAEs 50 receptor tyrosine kinase inhibitor 50 gemcitabine Gemzar ® 50 Pharmacodynamic 50 TDF FTC 50 efficacy tolerability 50 retinal vein occlusion induced 50 TPV r 50 nab paclitaxel 50 #.#mg/dL 50 bicifadine 50 aspartate aminotransferase AST 50 corrected QT interval 50 label multicenter 50 WOMAC scores 50 Folfox 50 Meets Primary Endpoint 50 salmeterol fluticasone propionate 50 Pivotal Phase 50 pioglitazone 50 PRECiSE 50 peginterferon alfa 2a #KD 50 telbivudine 50 endothelin receptor 50 nonsignificant 50 novel VDA molecule 50 blind placebo 50 tipranavir 50 KAPIDEX 50 tanespimycin 50 iloprost 50 Adalimumab 50 FDA defined valvulopathy 50 mcg albinterferon alfa 2b 50 Xelox 50 gemcitabine Gemzar 50 resected pancreatic cancer 50 MEND CABG II 50 pegylated interferon peg IFN 50 Relapsing Remitting Multiple Sclerosis 50 SBMs 50 intravenous dosing 50 prucalopride 50 cyclophosphamide doxorubicin vincristine 50 Phase #/#a 50 prokinetic agent 50 zoledronic acid 50 alfa 2b 50 posaconazole 50 μmol L 50 alicaforsen enema 50 HAM D 50 postmenopausal osteoporotic women 50 50 calcipotriene 50 paclitaxel carboplatin 50 Taxotere R 50 Cimzia ® certolizumab pegol 50 Zometa hazard 50 phase IIb study 50 VAPRISOL 50 By JENNIFER LEARN 50 CRLX# 50 Elitek 50 mRNA expression 50 CHOP chemotherapy 50 unstable angina UA 50 Fludara 50 p = NS 50 adjunctive ABILIFY 50 dosed 50 paricalcitol 50 golimumab CNTO 50 satraplatin Phase 50 FOLFOX4 alone 50 #mg doses [002] 50 Phase III randomized 50 NIH CPSI 49 clinical trials Multikine 49 DMARD 49 beclomethasone dipropionate 49 COPEGUS 49 placebo dexamethasone 49 HMG CoA reductase inhibitors 49 Severity MSCS score 49 pain palliation 49 AGILECT R 49 #q# deletion syndrome 49 placebo controlled dose escalation 49 ug kg 49 pertuzumab 49 blinded randomized placebo controlled 49 NYHA functional class 49 phase IIa clinical 49 Long Term Efficacy 49 nonrandomized 49 brachial artery flow 49 follicular NHL 49 Acetate Rectal Suppositories 49 RECIST Response Evaluation Criteria 49 enthesitis 49 fasting plasma 49 dacetuzumab 49 zoledronate 49 maximally tolerated dose 49 sustained virologic response 49 OADs 49 liposome injection 49 alanine aminotransferase 49 Phase IIb Trial 49 IV DHE 49 -#.# ± [002] 49 Solid Tumors criteria 49 daily Infergen 49 aPTT 49 univariate analysis 49 phase Ib 49 tocilizumab 49 liposomal doxorubicin 49 Key secondary endpoints 49 Expanded Disability Status 49 bleeding pallor 49 Lucentis monotherapy 49 Capecitabine 49 CK # administered 49 TACE 49 ROZEREM TM 49 pharmacokinetic characteristics 49 % CI #.#-#.# [003] 49 TNF alpha selectively neutralizing 49 mg Lucentis 49 LCP Tacro 49 oblimersen 49 bosutinib 49 dacarbazine chemotherapy 49 epoetin alpha 49 discontinuations 49 Hsp# Inhibitor 49 Novel Oral 49 Preclinical studies suggest 49 SCIg 49 Val HeFT 49 daily subcutaneous injections 49 multicenter Phase II 49 Kaplan Meier analysis 49 NGX# 49 Target Lesion Revascularization TLR 49 Phase Ia 49 quetiapine 49 antiretroviral naïve 49 beta 1a 49 esomeprazole 49 PROCTOCORT ® Suppository Hydrocortisone 49 dose titration 49 TNF Tumor Necrosis Factor 49 GOUT 49 BENICAR HCT 49 AZD# 49 Ziprasidone 49 MGd 49 CR nPR 49 achieved PASI 49 fostamatinib 49 Fulvestrant 49 eosinophilic asthma 49 MoxDuo 49 infliximab 49 C Reactive Protein 49 NOXAFIL Oral Suspension 49 Prospective Randomized Trial 49 subcutaneous enoxaparin 49 eplerenone 49 calcineurin inhibitor 49 mesalamine granules 49 ramipril 49 phase 2a 49 somatostatin analogue 49 XL# SAR# 49 strontium ranelate 49 Forodesine HCl 49 Score DAS# 49 serum leptin 49 raltegravir 49 Gemcitabine 49 L PPDS 49 preclinical efficacy 49 potently inhibited 49 Shows Statistically Significant 49 Dapagliflozin 49 postintervention 49 eculizumab therapy 49 HbA1c 49 XGEVA 49 #/#.# mcg 49 ongoing Phase 1b 49 Melphalan 49 Ereska 49 posttransplant 49 bortezomib refractory 49 sorafenib Nexavar ® 49 blinded placebo controlled 49 plus OBT 49 BRIM3 49 Randomized Double blind 49 safety tolerability pharmacokinetics 49 apremilast 49 5mg/kg 49 subscale scores 49 Cloretazine R VNP#M 49 octreotide acetate 49 Bosentan 49 dosed orally 49 mg/m2 IV 49 Dacogen injection 49 Xalatan R 49 telmisartan 49 Ranibizumab 49 β blockers 49 Score TOS 49 NEVO RES 49 ramelteon 49 Pharmacokinetic Study 49 severe exacerbations 49 microbiological eradication 49 squamous histology 49 #th Annual Interscience 49 HCV viral 49 Perforomist Inhalation Solution 49 lexidronam injection 49 transdermal estradiol 49 mCi kg 49 Neuropsychiatric Inventory 49 randomized blinded 49 mg/# hr 49 Safety Tolerability 49 prospective randomized multicenter 49 ALB # 49 idraparinux 49 EVIZON 49 peripherally acting 49 DLTs 49 pharmacodynamic profile 49 inhibitor RG# 49 NSABP B 49 TAXOTERE R 49 PEG interferon 49 achieving PASI 49 tamsulosin 49 dextromethorphan quinidine 49 lixisenatide 49 Monitoring ABPM 49 TIMP 1 49 mcg doses 49 systemic absorption 49 phase IIb clinical 49 XP# Transported Prodrug 49 BMI z 49 Phase 2a trial 49 #μg [001] 49 IDX# 49 nasopharyngitis 49 Randomised 49 Phase IIIb clinical 49 oral allopurinol 49 palonosetron 49 serologically active patients 49 SPIRIVA ® 49 left ventricular systolic 49 clomipramine 49 multicentre randomized double 49 ARIXTRA 49 piperacillin tazobactam 49 ziprasidone 49 prospectively stratified 49 APIDRA R 49 Naive Patients 49 DAPT 49 AZX# 49 RAPAFLO R 49 hour bronchodilation 49 FFNS 49 postdose 49 copies mL

Back to home page